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KaBACKGROUND BrS is an inherited sudden cardiac death syndrome. Less than 35% of BrS probands have genetically
identiﬁed pathogenic variants. Recent evidence has implicated SCN10A, a neuronal sodium channel gene encoding
Nav1.8, in the electrical function of the heart.
OBJECTIVES The purpose of this study was to test the hypothesis that SCN10A variants contribute to the development
of Brugada syndrome (BrS).
METHODS Clinical analysis and direct sequencing of BrS susceptibility genes were performed for 150 probands and
family members as well as >200 healthy controls. Expression and coimmunoprecipitation studies were performed to
functionally characterize the putative pathogenic mutations.
RESULTS We identiﬁed 17 SCN10A mutations in 25 probands (20 male and 5 female); 23 of the 25 probands (92.0%)
displayed overlapping phenotypes. SCN10A mutations were found in 16.7% of BrS probands, approaching our yield for
SCN5A mutations (20.1%). Patients with BrS who had SCN10A mutations were more symptomatic and displayed signif-
icantly longer PR and QRS intervals compared with SCN10A-negative BrS probands. The majority of mutations localized
to the transmembrane-spanning regions. Heterologous coexpression of wild-type (WT) SCN10A with WT-SCN5A in HEK
cells caused a near doubling of sodium channel current compared with WT-SCN5A alone. In contrast, coexpression of
SCN10A mutants (R14L and R1268Q) with WT-SCN5A caused a 79.4% and 84.4% reduction in sodium channel current,
respectively. The coimmunoprecipitation studies provided evidence for the coassociation of Nav1.8 and Nav1.5 in the
plasma membrane.
CONCLUSIONS Our study identiﬁed SCN10A as a major susceptibility gene for BrS, thus greatly enhancing our ability to
genotype and risk stratify probands and family members. (J Am Coll Cardiol 2014;64:66–79) © 2014 by the American
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ABB R E V I A T I O N S
AND ACRONYMS
AF = atrial ﬁbrillation
BrS = Brugada syndrome
CCD = cardiac conduction
defect
Co-IP = coimmunoprecipitation
ECG = electrocardiogram
ERS = early repolarization
syndrome
INa = sodium channel current
MAF = minor allele frequency
PRI = PR interval
RBBB = right bundle branch
block
SCD = sudden cardiac death
VF = ventricular ﬁbrillation
VT = ventricular tachycardia
WT = wild-type
J A C C V O L . 6 4 , N O . 1 , 2 0 1 4 Hu et al.
J U L Y 8 , 2 0 1 4 : 6 6 – 7 9 SCN10A Mutations Associated With BrS
67B rugada syndrome (BrS), which was introducedas a new clinical entity in 1992 (1), is aninherited sudden cardiac death (SCD) syn-
drome characterized by the appearance of prominent
J waves or ST-segment elevation in leads V1 to V3
on an electrocardiogram (ECG). An outward shift in
the balance of ion channel currents ﬂowing during
the early phases of the cardiac action potential have
been shown to create the substrate for the develop-
ment of life-threatening arrhythmias in BrS (2).
The syndrome has been associated with 13 geno-
types (BrS1 to BrS13) displaying autosomal dominant
inheritance (3,4). To date, more than 300 BrS-
related mutations in SCN5A have been described
(5), accounting for the vast majority (>75%) of BrS
genotype-positive cases but only 11% to 28% of total
BrS probands. Approximately 65% of BrS probands
remain genetically undetermined. Thus, there is a
pressing need to identify new BrS susceptibility
genes for the purpose of early diagnosis, risk stratiﬁ-
cation, and targeted treatment (6,7). A similar situa-
tion is encountered in other inherited cardiac
arrhythmia syndromes, including early repolarization
syndrome (ERS), cardiac conduction disease (CCD),
bradycardia, idiopathic ventricular ﬁbrillation (VF),
atrial ﬁbrillation (AF), and right bundle branch block
(RBBB).SEE PAGE 80Nav1.8 (encoded by SCN10A), like Nav1.5 (encoded
by SCN5A), is a tetrodotoxin-resistant voltage-gated
sodium channel located adjacent to SCN5A on human
chromosome 3p21–22 (8,9). Until recently, Nav1.8 was
principally considered a neuronal sodium channel
involved in nociception. The amino acid sequences of
human Nav1.8 and Nav1.5 are similar (70.4%). Recent
evidence has implicated SCN10A in the electrical
function of the heart (10–12). Several genome-wide
association studies have reported that single nucleo-
tide polymorphisms in SCN10A are associated with
CCD and arrhythmogenesis (13–21). The present study
examined the hypothesis that variations in SCN10A
contribute to BrS by modulating the expression of the
Nav1.5 current, the principal cardiac sodium channel.
Preliminary results have been reported in abstract
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Detailed methods are provided in the Online
Appendix.
CLINICAL ANALYSIS AND PARTICIPANTS.
The clinical diagnosis of BrS was on the basis
of criteria provided in the 2005 Consensus
Conference document (23), and the clinical
diagnosis of ERS was on the basis of criteria
suggested in our recent review of the J-wave
syndromes (24). Informed consent was ob-
tained from all patients upon referral to the
Masonic Medical Research Laboratory for ge-
netic testing, and patients were tracked
anonymously. This study was approved by
the regional institutional ethics review board
and conducted according to Declaration of
Helsinki principles. For each patient, we
collected information on age at time of diag-
nosis, sex, clinical presentation, family his-
tory, and therapy.
GENET IC SCREENING AND ANALYS IS . Genomic
DNA was extracted from peripheral blood leukocytes
and ampliﬁed. All known BrS genes and SCN10A
were ampliﬁed and analyzed by direct sequencing
as previously described (25). The primer sequences
for SCN10A are shown in Online Table 1 (reference
sequence: NM_006514). More than 200 ethnically
matched, healthy controls, plus all available online
databases for allele frequency, conservation score,
and in silico pathogenic prediction tools, were probed
for prediction of pathogenicity of the variants found.
COEXPRESS ION OF NAV1 .5 AND NAV1 .8 FOR
CO IMMUNOPREC I P I T A T I ON ANALY S I S AND
ELECTROPHYS IOLOG ICAL INVEST IGAT IONS .
Site-directed mutagenesis was performed on full-
length human wild-type (WT) and mutant SCN10A-
3XFLAG complementary DNA cloned in pCMV2
vector, the WT SCN3B cloned in pCMV6-XL6 vector,
and the WT SCN5A cloned in pcDNA3.1. Coim-
munoprecipitation (Co-IP) studies were performed
using HEK293 cells transfected with SCN5A,
and SCN10A and SCN3B plasmids were also used
for studies. Total protein was isolated 24 h after
transfection with lysis buffer supplemented withnal Institutes of Health (HL47678) and the New York
s. All other authors have reported that they have no
ntin Fuster.
r. Valentin Fuster.
3, 2014, accepted April 23, 2014.
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68protease inhibitors for Co-IP experiments. Mem-
brane currents were measured with whole-cell
patch-clamp techniques using TSA201 cells as pre-
viously described (25).
STATISTICAL ANALYSIS. Data are presented as mean
 SD unless otherwise noted. For statistical analysis,
2-tailed Student t test and analysis of variance
coupled with Student–Newman–Keuls test were used
to compare 2 groups and more than 3 groups of
continuous variables separately. Chi-square test was
used for comparison of categorical variables (Sigma-
Stat; Systat Scientiﬁc Inc., San Jose, California). Dif-
ferences were considered statistically signiﬁcant at a
value of p < 0.05.
RESULTS
STUDY POPULATION. We systematically evaluated
150 unrelated patients with BrS and 17 family members
using genetic screening (Table 1). Most patients were
male (n ¼ 101; 67.3%), with a mean age at diagnosis of
44.5  16.1 years. A total of 116 patients (77.3%) wereTABLE 1 Demographics of Patients With BrS
Probands With BrS
Overall SCN10Aþ SC
Patient demographics
Number of probands 150 25 (yield 16.67)
Family history of
cardiac events/
unexplained
sudden death
29 (19.33) 4 (16.00) 25
Age at diagnosis, yrs 44.48  16.10 42.50  13.56 44.83
Male 101 (67.33) 20 (80.00) 81
Female 49 (32.67) 5 (20.00) 44
CCD 36 (24.00) 12 (48.00) 24
ER* 24 (16.00) 8 (32.00) 16
Bradycardia 24 (16.00) 5 (20.00) 19
VT/VF 33 (22.00) 12 (48.00) 21
AF 13 (8.67) 2 (8.00) 11
Symptoms
Asymptomatic 34 (22.67) 1 (4.00) 33
Syncope 39 (26.00) 10 (40.00) 29
SCD 20 (13.33) 6 (24.00) 14
Chest pain 11 (7.33) 5 (20.00) 6
Other symptoms† 54 (36.00) 12 (48.00) 42
Electrocardiography
Heart rate, beats/min 73.82  16.58 72.58  16.35 74.10
PR interval, ms 175.97  38.23 193.44  31.79‡ 171.47
QRS interval, ms 98.84  17.82 105.72  18.85‡ 97.26
QT interval, ms 378.94  42.43 384.44  38.67 377.70
QTc interval, ms 414.40  36.22 416.05  37.42 414.04
Values are n, n (%), or mean  SD. *ER pattern other than V1 to V3. †Other symptoms incl
and SCN10A groups.
AF ¼ atrial ﬁbrillation; BrS ¼ Brugada syndrome; CCD ¼ cardiac conduction disease; ER
ventricular ﬁbrillation.symptomatic, including 39 (26.0%) with syncope and
20 (13.3%) who experienced cardiac events, docu-
mented as aborted cardiac arrest or SCD. Twenty-nine
(19.3%) had a family history of cardiac events or SCD. A
type 1 Brugada ECG pattern, characterized by a
prominent J-wave appearing as a coved type ST-
segment elevation, was observed spontaneously in
57 patients (38.0%) (Fig. 1A), appeared after treatment
with sodium channel blockers in 76 patients (50.7%)
(Fig. 1B) or during fever in the remaining 17 patients
(11.3%) (Fig. 1C). Some patients with BrS also displayed
ERS (Fig. 1D), CCD (Fig. 1E), RBBB (Fig. 1F), ventricular
tachycardia (VT)/VF, or AF.
MUTATION YIELD AND ANALYSIS. Overall, 17 puta-
tive pathogenic SCN10A rare variants (16 missense
and 1 frameshift mutation) were identiﬁed in 25 pro-
bands (Fig. 2A, Tables 2 and 3). Seven family members
were positive for SCN10A variants. Eleven mutations
were identiﬁed only once (64.7%), whereas 6 variants
were found in multiple unrelated patients (Fig. 2B).
The most frequent mutation was R14L (Fig. 1A), which
was carried by 4 BrS probands. The other mutations/Probands With BrS and CCD
N10A Overall SCN10Aþ SCN10A
125 36 12 (yield 33.33) 24
(20.00) 8 (22.22) 3 (25.00) 5 (20.83)
 16.61 44.75  19.92 43.25  15.15 45.50  22.18
(64.80) 27 (75.00) 9 (75.00) 18 (75.00)
(35.20) 9 (25.00) 3 (25.00) 6 (25.00)
(19.20) 36 (100.00) 12 (100.00) 24 (100.00)
(12.80) 8 (22.22) 3 (25.00) 5 (20.83)
(15.20) 10 (27.78) 3 (25.00) 7 (29.17)
(16.80) 12 (33.33) 7 (58.33) 5 (20.83)
(8.80) 1 (2.78) 0 (0.00) 1 (4.17)
(26.40) 9 (25.00) 1 (8.33) 8 (33.33)
(23.20) 10 (27.78) 4 (33.33) 6 (25.00)
(11.20) 3 (16.67) 3 (25.00) 3 (12.50)
(4.80) 3 (8.33) 3 (25.00) 0 (0.00)
(33.60) 11 (33.33) 4 (33.33) 8 (33.33)
 16.69 68.07  17.77 72.00  21.39 65.11  15.31
 38.42 218.29  34.59 217.42  24.20 218.77  39.66
 17.28 103.47  19.34 107.67  24.01 101.38  16.72
 43.30 398.28  44.45 388.67  48.18 403.08  42.71
 36.11 416.29  42.24 420.40  49.82 414.23  38.92
uded palpitations, dizziness, sleep apnea, and coma. ‡p < 0.05 between the SCN10Aþ
¼ early repolarization; SCD ¼ sudden cardiac death; VT/VF ¼ ventricular tachycardia/
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FIGURE 1 Representative Cases of the Different BrS Phenotypes Associated With the SCN10A Mutations/Rare Variants Identiﬁed
Each panel (A to F) shows the ECG phenotype, amino acid alignments of the mutated residue position in a number of mammalian species, and DNA chromatogram of WT
and mutant SCN10A. For the pedigrees in D and E, þ/- indicates heterozygous for the mutation, circles represent female subjects, and squares represent male subjects.
The arrow indicates the proband. Clinically affected and unaffected subjects are labeled in black and white, respectively. BrS ¼ Brugada syndrome; CCD ¼ cardiac
conduction disease; ECG ¼ electrocardiogram; ERS ¼ early repolarization syndrome; RBBB ¼ right bundle branch block; SCD ¼ sudden cardiac disease; WT ¼ wild-type.
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69rare polymorphisms present in the population were
V1697I (n ¼ 3), G1662S (n ¼ 3), I206M (n ¼ 2), I1225T
(n ¼ 2), and R1869C (n ¼ 2). Most variants localized to
the transmembrane-spanning regions (P-loop in
42.3% and S1 to S4 in 23.1% of BrS probands) (Fig. 2C).
Among the 25 SCN10A mutations or rare variant
carriers, 6 carried a secondary mutation in 1 of the 12
known BrS susceptibility genes (24.0%) (Table 2).
F938YFSX12, G1406D, and N1715T are novel variantsin SCN10A that were not previously reported
(Table 3). A majority of missense mutations (13 of 16)
were in highly conserved residues and showed minor
allele frequencies (MAF) of 0 to 0.002 in control da-
tabases. None were found in more than 400 reference
alleles in our healthy controls. All but 1 (T137M) of
these 13 mutations were predicted to be damaging by
in silico prediction tools (Table 3). The MAF of S1337T
was 0.0047, that of V1697I was 0.0044, and that of
T137M D1 D2 D3 D4F386C
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FIGURE 2 Clinical and Genetic Prevalence of SCN10A Mutations/Rare Variants in Probands With BrS Identiﬁed in the Present Study
(A) Schematic showing the topology of Nav1.8, the pore-forming alpha subunit encoded by SCN10A and the location of putative BrS-causing
variants. (B) Frequency distribution of SCN10A mutations/rare variants in patients with BrS. (C) Percentage of mutations/rare variants in
patients with BrS by location. (D) Mutation detection yield by gene in Masonic Medical Research Laboratory cases of BrS. (E and F) Bar graph
showing the age and sex distribution of the patients with BrS. N/A ¼ not available; other abbreviations as in Figure 1.
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70I206M was 0.0046 in our controls. All 4 cases carrying
these 3 rare polymorphisms were middle-aged men
(31 to 58 years of age), and 3 were symptomatic.
OVERLAPPING PHENOTYPES OF PROBANDS WITH
SCN10A VARIANTS. With a positive proband yield of
16.7%, the prevalence of SCN10A in BrS probands
approached our historical yield for SCN5A mutations,
which was 20.1% (Fig. 2D). Of the 25 cases of SCN10Aþ
BrS, 23 (92.0%) displayed overlapping phenotypes
(Table 2). In cases of BrS with overlapping phenotypes
(such as CCD and early repolarization patterns in
leads other than V1 to V3), the SCN10Aþ positive
proband yield was greater (Table 1). Patients with
BrS who had SCN10A mutations were more symp-
tomatic (syncope, SCD, chest pain) and displayed
longer PR and QRS intervals (193.4  31.8 ms and105.7  18.9 ms) compared with SCN10A BrS pro-
bands (171.5  38.4 ms and 97.3  17.3 ms; p < 0.05).
No differences in heart rate, QT interval, or Bazett
QTc interval were observed. The yield of SCN10Aþ BrS
probands was greater in male (19.8%) than in female
(10.2%) subjects in general (Fig. 2F). This difference
was not observed in the subgroup of patients with BrS
who had CCD but was more obvious in the patients
with BrS without CCD. Figure 2E shows yield as a
function of age. The yield of probands with a spon-
taneous type 1 Brugada ECG pattern was 15.8%, which
was similar to that in cases of BrS unmasked with a
sodium channel blocker (14.5%). Interestingly, BrS
probands diagnosed during fever showed a much
higher yield (5 of 17; 29.4%) for SCN10A variants; all
were male.
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71The average PR interval (PRI) for BrS probands with
CCD was 218.3  34.59 ms (maximum PRI: 328 ms).
The yield of SCN10Aþ in this cohort was signiﬁcantly
higher (33.3%) than in those without CCD (11.4%)
(p < 0.01). Compared with SCN10A subjects, those
with SCN10Aþ CCD and BrS had a higher incidence of
VT/VF, SCD, and chest pain (Table 1).
A total of 24 patients with BrS displayed an early
repolarization pattern in leads other than V1 to V3.
Seven of these probands and 2 family members were
positive for SCN10A mutations, including 5 probands
with global J-point/wave elevation (ERS3: 71.4%),
indicating a higher correlation of SCN10A with BrS
and ERS compared with BrS phenotype alone. In the
case pictured in Figure 1D, the proband presented
with global J-point elevation (ERS/BrS), bradycardia,
and a family history of SCD. He and his affected
family members carried the same SCN10A-G1662S
mutation (details are provided in the Online
Appendix).
SCN10A mutations were identiﬁed in 12 of the 33
patients with BrS presenting with VT/VF. BrS
appeared spontaneously in 5 cases (41.7%), 2 cases
were unmasked during fever (16.7%), and the rest
were unmasked with use of sodium channel blockers
(41.7%). Including those with pediatric bradycardia,
the average heart rate of the 24 probands with
bradycardia and BrS was 51.4  1.7 beats/min. SCN10A
mutations were identiﬁed in 5 cases. Four family
members in 3 families also were positive for SCN10A
mutations (G1662S for 2, R14L for 1, and F938Y FSX12
for 1), indicating clear genetic penetrance. SCN10A-
S1337T and R1869C were found in 2 AF probands with
BrS phenotypes. The SCN10A-N1715 mutant carrier
presented with BrS and an RBBB ECG pattern, an
overlapping phenotype recently highlighted by
Aizawa et al. (26) (Fig. 1F).
FUNCTIONAL EXPRESSION STUDIES. For functional
characterization, SCN5A/WT, SCN10A/WT, or SCN5A/
WT þ SCN10A/WT was coexpressed with SCN3B/WT
in HEK293 cells (Fig. 3A). Peak sodium channel cur-
rent (INa) amplitude at 35 mV was 462.8  83.2 pA/
pF for SCN5A/WT þ SCN3B/WT. Addition of SCN10A/
WT yielded a near doubling of peak INa to 859.7 
98.9 pA/pF (p < 0.01). In contrast, coexpression of
SCN10A/WT þ SCN3B/WT alone generated very low
amplitude current (12.2  3.3 pA/pF; p < 0.01
compared with the other 2 groups) (Fig. 3B). Coex-
pression of the SCN10A mutants, R14L and R1268Q,
with SCN5A/WT and SCN3B/WT caused a major loss of
function of INa (Figs. 3C to 3I). SCN10A-R14L reduced
peak INa density to 177.5  49.5 pA/pF (p < 0.01 vs.
SCN10A-WT) and caused a signiﬁcant positive shift ofhalf-activation voltage (p < 0.05). SCN10A-R1268Q
reduced the current density to 133.9  36.6 pA/pF
(p < 0.01 vs. SCN10A/WT) with no change in activa-
tion parameters. The half-inactivation voltage of
SCN10A-R1268Q was 7.7 mV more negative than that
of SCN10A-WT when coexpressed with SCN5A-WT þ
SCN3B-WT (p < 0.05). Recovery from inactivation was
similar in the 2 mutant groups, but both were slower
than WT channels (p < 0.05 in both sf and ss,
respectively). The gating defects caused by SCN10A-
R14L and SCN10A-R1268Q served to reduce sodium
channel availability (Online Table 2).
CO-IP STUDY. We examined the capability of Nav1.5
to physically interact with Nav1.8 using Co-IP. The
channels were expressed in HEK293 cells either alone
or in combination and isolated by pull-down using an
antibody to the FLAG on SCN10A. Figure 4A shows the
protein input for each condition, demonstrating the
presence of the transfected proteins under the
appropriate conditions. Figure 4B shows the associa-
tion between Nav1.5 and Nav1.8 when coexpressed
(lane 5, bottom panel). This interaction was lost when
the pull-down antibody was omitted (lane 4, bottom
panel) and did not occur due to in vitro mixing of the
protein lysates (lane 6, bottom panel).
DISCUSSION
SCN10A IN THE HEART AND ITS ROLE IN ARRHYTH-
MOGENESIS. SCN5A and SCN10A are located in close
proximity to each other in chromosome 3p22. In 1997,
SCN10A protein (also referred to as PN3, SNS, and
hereafter Nav1.8) was initially shown to be speciﬁcally
expressed in rat and human dorsal root ganglia (27).
Real-time polymerase chain reaction and immuno-
staining methodologies have detected a low level of
expression of the SCN10A gene product in mouse and
human heart tissues, with somewhat higher levels in
the Purkinje system (12,15,18). Nav1.8 immunoreac-
tivity was detected in intracardiac neurons and
ganglia in human myocardium (28). With the in situ
hybridization method, SCN10A displayed a similar
distribution pattern of Scn5a in mouse hearts (10).
These ﬁndings notwithstanding, some researchers
deny the existence of Nav1.8 in cardiac myocytes. For
example, Verkerk et al. (11) reported that SCN10A
expression modulates cardiac electrical activity pri-
marily by regulating the ﬁring patterns of intracardiac
neurons. Conﬂicting data also resulted from other
in vivo and in vitro experimental studies in the ani-
mal models (12,15).
The localization, expression level, and functional
role of Nav1.8 in the heart remain highly controversial.
TABLE 2 Clinical and Genetic Characteristics of Affected Probands
Patient #
General
Information Symptoms Arrhythmia
Age at
Diagnosis,
yrs Sex FH Syncope SCD
Chest
Pain Other* BrS/ERS
ER Pattern
Other Than V1–V3 CCD Bradycardia
1 65 M N N N N Y BrS (spontaneous BrS/RBBB) N Y (I AVB) N
2 50 F Y N N Y Y BrS (spontaneous) I, aVL Y (I AVB) N
3 42 F N Y N Y Y BrS (spontaneous) N N N
4 44 M N Y N N N BrS (spontaneous) N N N
5 20 M N Y Y N N BrS/ERS3 (spontaneous/procainamideþ) II, III, aVF N N
6 19 M N N N Y N BrS (procainamideþ) N N N
7 36 M N N N N Y BrS (ajmalineþ) N N N
8 19 M Y Y Y Y Y BrS/ERS3 (ﬂecainideþ) II, III, aVF, V4–V6 Y (I AVB) Y
9 39 M N Y N N N BrS (ajmalineþ) I, aVL N N
10 46 M N Y N N Y BrS (procainamideþ) N N N
11 37 M N N/A N/A N/A N/A BrS (ajmalineþ) N Y (I AVB) N
12 49 F Y Y N N Y BrS (spontaneous) N Y (I AVB) N
13 44 M N/A N N N Y BrS (feverþ) N N N
14 27 M N N Y N N BrS (feverþ) N Y (I AVB) N
15 44 M N Y N N N BrS (feverþ) N Y (I AVB) N
16 56 M N/A N N N Y BrS (feverþ) N N N
17 31 M Y N N N N BrS (ajmalineþ) N Y (I AVB) N
18 65 M Y Y Y N N BrS/ERS3 (spontaneous) II, III, aVF N Y
19 49 M N/A N N N Y BrS (feverþ) aVL N N
20 58 M N Y N N N BrS (ajmalineþ) N Y (I AVB) N
21 46 F N N Y N N BrS/ERS3 (spontaneous) I, II,III, aVF, V5–V6 Y (I AVB) Y
22 65 M N N Y N N BrS (ﬂecainideþ) N Y (I AVB) Y
23 28 M N N N Y N BrS (spontaneous/procainamideþ) N Y (I AVB) N
24 43 M N N Y N Y BrS (procainamideþ) N N N
25 47 F N N N N Y BrS/ERS3 (ajmalineþ) II, III, aVF, V4–V6 N Y
Total 42.5  13.6 F5/M20 (80) 5 (20) 10 (40) 7 (28) 5 (20) 12 (48) 25 (100) 8 (32) 12 (48) 5 (20)
SCN10Aþ 41.2  13.7 F3/M16 (84) 5 (26) 9 (47) 4 (21) 4 (21) 10 (53) 19 (100) 6 (32) 8 (42) 2 (10)
SCN10A and
other genesþ
47.8  12.8 F2/M4 (67) 0 (0) 1 (17) 3 (50) 1 (17) 2 (33) 6 (100) 2 (33) 4 (67) 3 (50)
Continued on the next page
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72Nonetheless, our results support the conclusion that
SCN10A variants play a key role in developing
arrhythmogenic J-wave syndromes, including both
BrS and ERS, likely through a direct effect on
Nav1.5-mediated cardiac INa (Central Illustration).
A key role for Nav1.8 in human cardiac electrophysi-
ology is supported by genome-wide association
studies, showing that SCN10A plays an important
role in cardiac conduction disease by inﬂuencing
the duration of the PRI and QRS interval as well as
heart rate and arrhythmic risk. Several independent
loci within SCN10A have been identiﬁed, includ-
ing rs6795970 (13–18), rs6798015 (16,19), rs6800541
(16,20), rs7430477 (16), and rs12632942 (15). A recent
genome-wide association study of 312 subjects with
BrS and 1,115 controls reported a signiﬁcant associa-
tion signal at the SCN10A locus (rs10428132), providingadditional support for a role for SCN10A variants, in
this case 30–untranslated region or intronic, in the
development of BrS (21).
CLINICAL AND GENETIC FINDINGS RELATED TO
SCN10A. We identiﬁed 17 putative pathogenic
SCN10A variants in 25 of the 150 BrS probands
screened. A positive proband yield of 16.7% app-
roached our historical yield of 20.1% for SCN5A and a
yield of 11% to 28% (21% average) reported in the in-
ternational compendium of SCN5A mutations (5).
In our study, as in the international compendium
study, there was a male predominance of the BrS
phenotype (67% vs.78%). The latter has a similar yield
between male and female subjects (20% vs. 22%,
respectively).This was not the case in our screen for
SCN10A mutations, where the yield was greater for
male subjects (20% vs. 10%).
TABLE 2 Continued
Arrhythmia
Genetic Rare
Variants ECG
TreatmentVT/VF AF SCN10A
Other
Suspected
Gene
Heart Rate,
beats/min
PR Interval,
ms
QRS Interval,
ms
QT Interval,
ms
QTc Interval,
ms
Y (induced) N N1715T N 71 220 72 426 463 ICD
N N R14L N 73 234 112 402 443
Y (induced) N F938YFSX12 N 68 160 120 400 426 ICD
Y (induced) N G1662S N 79 190 120 380 436 Quinidine
N N S242T N 67 170 105 376 396
Y (induced) N R14L N 66 185 113 397 416
Y (spontaneous) N G1406D N 73 150 110 400 442 ICD
Y (spontaneous) N G1662S N 44 200 120 410 352
N N I206M/V1697I N 78 168 80 340 388
N Y S1337T N 69 148 105 418 448
N N T137M N 59 205 72 350 348
Y (spontaneous) N R1268Q N 79 170–200 102 380 436 ICD
N N I1225T N 80 180 110 350 404
Y (during fever) N G1662S N 120 220 120 300 387 ICD, metoprolol
Y (during fever) N I1225T N 103 200 116 400 525 ICD
N N L388P N 86 180 112 350 418
Y (induced) N V1697I N 75 200 120 360 403
Y (spontaneous) N R14L N 54 194 94 400 378 ICD, amiodarone
N N R14L N 88 130 110 340 411
N N I206M/V1697I CACNB2B 84 210 100 344 408 ICD, metoprolol
N N V620I SCN5A 53 280 84 432 406 ICD
Y (spontaneous) N F386C CACNA1C 55 200 116 484 464 ICD
N N D1080N SCN5A 71 240 158 376 409 ICD
N Y R1869C KCNJ8 64 192 84 372 385
N N R1869C CACNB2B 56 180 88 424 408
12 (48) 2 (8) 25 72.6  16.3 193.4  31.8 105.7  18.9 384.4  38.67 416.1  37.4 ICD-11 (44.0)
11 (58) 1 (5) 19 75.4  16.8 186.0  26.9 105.9  15.6 377.8  32.9 416.9  40.9 ICD-7 (36.4)
1 (17) 1 (17) 6 63.8  12.0 217.0  37.0 105.0  28.7 405.3  51.0 413.3  26.4 ICD-4 (66.7)
Values are mean  SD or n (%). *Other symptoms included palpitations, dizziness, and coma.
AVB ¼ atrioventricular block; ECG ¼ electrocardiography; ERS ¼ early repolarization syndrome; ERS3 ¼ type 3 early repolarization syndrome; FH ¼ family history of cardiac events/unexplained sudden
death; HR ¼ heart rate; ICD ¼ implantable cardioverter-deﬁbrillator; N/A ¼ not available; RBBB ¼ right bundle branch block; other abbreviations as in Table 1.
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73In our study, 66.7% of SCN10A mutations were
localized to transmembrane and pore-forming do-
mains; this is in comparison to the nearly 75% re-
ported in the SCN5A compendium. Of all BrS-related
SCN10A variants, one was a frameshift and the rest
were missense mutations (94.1%), whereas in the
compendium of SCN5A mutations, two-thirds were
reported to be missense mutations.
Six of the 25 cases reported were also found to
carry a second potentially pathogenic BrS mutation
(Table 2). As such, the number of SCN10A variants
that we counted as potentially responsible for the
clinical phenotype could be an overestimate. This
notwithstanding, the 3 mutations in calcium channel
genes were found in patients with a prolonged PRI
(>180 ms) and normal QTc interval, pointing to a clear
predominance of the SCN10A mutation leading to a
loss of function of INa. The KCNJ8 mutation likewisewas accompanied by a prolonged PRI. The 2 SCN5A
mutations were both accompanied by very prolonged
PRI (240 to 280 ms), suggesting that both the SCN5A
and SCN10A variants contributed to the clinical
phenotype. Interestingly, the yield of BrS probands
unmasked by fever was much higher in the case of
SCN10A versus SCN5A mutations (29.4% vs. 17.2%)
(Dan Hu et al., unpublished data, February 2014).
There was a higher association with SCD and syncope
in the case of SCN10A versus SCN5A mutations. Also
interesting is the larger number of complaints of
chest pain in the SCN10Aþ group than in the SCN10A
group, which was not observed when SCN5Aþ and
SCN5A cases were compared.
More than 90% of the subjects with SCN10Aþ BrS
presented with mixed phenotypes, the most common
of which was CCD. It is not surprising that, as with
SCN5Amutations (39% when the PRI was >200 ms vs.
TABLE 3 Summary of SCN10A Rare Variants Associated With BrS
Rare
Variant Reported ID Exon Type
Change in
Nucleotide
Change in
Amino Acid Codons Location
Global MAF
(1000 genome)
Global MAF
(ESP)
Number of
Unrelated
Subjects
Number of
Family
Members
SIFT
Score
SIFT
Prediction
PolyPhen
Score PolyPhen Prediction
Conservation
(phastCons)*
Conservation
(GERP)†
R14L rs141207048 1 Missense p.Arg14Leu c.41G>T CGT/CTT N-terminal 0.002 0.002153 5 2 0 Deleterious 0.998 Probably damaging 0.987 2.32
T137M rs148663098 3 Missense p.Thr137Met c.410C>T ACG/ATG DI–SI 0 0.000077 1 0 1.00 Tolerated 0.022 Benign 0.077 3.26
I206M rs74717885 5 Missense p.Ile206Met c.618A>G ATA/ATG DI–SIII 0.048 0.01161 4 0 0.01 Deleterious 0.082 Benign 0.001 0.84
S242T rs140288103 6 Missense p.Ser242Thr c.724T>A TCA/ACA DI–S4/S5 0 0.000231 1 0 0 Deleterious 0.999 Probably damaging 0.997 4.69
F386C rs78555408 9 Missense p.Phe386Cys c.1157T>G TTC/TGC DI–S6 0.002 N/A 1 1 0 Deleterious 1.000 Probably damaging 1.000 5.21
L388P rs199734710 9 Missense p.Leu388Pro c.1163T>C CTG/CCG DI–S6 0.001 0.000231 1 0 0 Deleterious 1.000 Probably damaging 1.000 5.21
V620I rs151303346 12 Missense p.Val620Ile c.1858G>A GTC/ATC DI/DII 0 0.000384 1 0 0.03 Deleterious 0.999 Probably damaging 0.818 4.6
F938Y
FSX12
N/A 16 Frame shift p.Phe938 Tyr
FsX12
c.2813-2814
del in A
‡ DII/DIII N/A N/A 1 1 N/A N/A N/A N/A N/A N/A
D1080N TMP ESP 3
38765035
18 Missense p.Asp1080Asn c.3238 G>A GAC/AAC DII/DIII 0 0.000077 1 0 0.17 Tolerated 0.967 Probably damaging 0.75 4.82
I1225T rs139638446 20 Missense p.Ile1225Thr c.3674 T>C ATT/ACT DIII–S4 0 0.000461 2 0 0 Deleterious 1.000 Probably damaging 0.992 4.45
R1268Q rs138832868 21 Missense/
near-splice
p.Arg1268Gln c.3803G>A CGG/CAG DIII–S4/S5 0.001 0.002076 1 1 0 Deleterious 0.741 Probably damaging 1.000 4.14
S1337T rs11711062 22 Missense p.Ser1337Thr c.4009T>A TCC/ACC DIII–S5/S6 0.001 0.004536 1 0 0.61 Tolerated 0.059 Benign 0 9.34
G1406D N/A 24 Missense p.Gly1406Asp c.4217G>A GGC/GAC DIII–S6 N/A N/A 1 0 0 Deleterious 0.999 Probably damaging 1.000 5.11
G1662S rs151090729 27 Missense p.Gly1662Ser c.4984G>A GGC/AGC DIV–S5/S6 0.001 0.001307 3 2 0 Deleterious 1.000 Probably damaging 0.969 5.38
V1697I rs77804526 27 Missense p.Val1697Ile c.5089G>A GTA/ATA DIV–S5/S6 0.004 0.010072 4 0 0.37 Tolerated 0.098 Benign 0.138 0.24
N1715T N/A 27 Missense p.Asn1715Thr c.5144A>C AAC/ACC DIV–S6 N/A N/A 1 0 0 Deleterious 1.000 Probably damaging 1.000 4.19
R1869C rs141648641 27 Missense p.Arg1869Cys c.5605 C>T CGC/TGC C-terminal 0 0.000923 2 0 0 Deleterious 1.000 Probably damaging 0.945 5.09
*This is a number between 0 and 1 that describes the degree of sequence conservation among 17 vertebrate species; these numbers were downloaded from the University of California Santa Cruz Genome site (http://genome.ucsc.edu/). †The Genomic Evolutionary Rate
Proﬁling (GERP) score was obtained from the GERP website in September 2011. It ranges from 12.3 to 6.17, with 6.17 being the most conserved. ‡T2813 and C2814 are replaced by an A, causing a frameshift resulting in a stop codon 12 AA later.
1000 genome ¼ The 1000 Human Genome Project Database; ESP ¼ Exome Sequencing Project; MAF ¼ minor allele frequency; SIFT ¼ Sorting Intolerant From Tolerant.
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FIGURE 3 Electrophysiological Effect of SCN10A on Cardiac INa When Coexpressed With SCN5A and SCN3B in HEK293 Cells
(A and B) Superimposed traces and bar graph depicting peak INa recorded from coexpression of SCN10A/WT þ SCN3B/WT, SCN5A/WT þ SCN3B/WT, and
SCN5A/WT þ SCN10A/WT þ SCN3B/WT. **p < 0.01 vs. SCN5A/WT þ SCN10A/WT þ SCN3B/WT, ##p < 0.01 vs. SCN5A/WTþSCN3B/WT. (C to E) Repre-
sentative INa traces, current-voltage relationship, and voltage dependence of activation for SCN10A/WT, SCN10A/R14L, and SCN10A/R1268Q when coex-
pressed with SCN5A/WT þ SCN3B/WT. (F and G) Representative steady-state inactivation and recovery traces recorded from WT and mutant channels.
(H and I) Boltzmann distributions of voltage-dependent channel inactivation and recovery curve with a double-exponential ﬁt for the 3 groups. All related
values and the number of cells used are shown in Online Table 2. INa ¼ sodium channel current; other abbreviations as in Figure 1.
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FIGURE 4 Representative Experiments Demonstrating Physical Interaction Between Nav1.8 and Nav1.5
(A) Protein input and (B) protein isolated by the antibody pull-down coimmunoprecipitation (Co-IP). Lanes 1 to 6 correspond to the following
experimental conditions: (1) nontransfected, (2) Nav1.8 expressed alone, (3) Nav1.5 expressed alone, (4 and 5) Nav1.8 and Nav1.5 coexpressed,
and (6) mixed lysates from lanes 3 and 4. B shows that the pull-down of Nav1.5 is speciﬁc to Nav1.8 cellular coexpression.
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768% when the PRI was <200 ms) (6), the yield of
SCN10A mutants was much higher in BrS probands
with a prolonged PRI (31% in those with a PRI >200
ms vs.11% in those with a PRI <200 ms).
We observed a high prevalence of SCN10A variants
associated with BrS and ERS, most of which: 1) are in
amino acid residues that are highly conserved in
mammalian species; 2) exhibit a very low MAF in
controls; 3) are predicted by in silico models to be
pathogenic; 4) show good genotype-phenotype cor-
relation in cases in which family pedigrees are avail-
able; and 5) show a major loss of function in INa in
the 2 cases in which the variants were functionally
coexpressed with SCN5A, suggesting that SCN10A is
an important susceptibility gene for BrS and for other
cardiac syndromes, including CCD, ERS, AF, VT/VF,
RBBB, and bradycardia. SCN10A is known to be
involved in nociception (29). Our referring physicians
did not report altered nociception other than an
increased incidence of chest pain.
MECHANISMS UNDERLYING SCN10A MODULATION
OF ELECTRICAL FUNCTION OF THE HEART. Alpha-
subunit interactions have previously been shown
to aggravate as well as ameliorate disease pheno-
types. The combination of SCN2A and KCNQ2 muta-
tions causes severe seizure manifestations (30), an
Scn8a mutation has been shown to compensate for
haploinsufﬁciency of Scn1a (31), and SCN9A muta-
tions are known to modify the severity of SCN1A-
related Dravet syndrome (32). A recent study of BrS
reported a dominant-negative effect of SCN5Amutant
channels interacting with SCN5A-WT channels (33).
Given their proximity to one another, SCN5A and
SCN10A may be subject to common regulatory
mechanisms, such as transcriptional control by TBX3
and TBX5 (10).We hypothesize that SCN10A modulates the activ-
ity of the canonical cardiac sodium channel encoded
by SCN5A in the heart. Our coexpression studies
provide evidence in support of this hypothesis,
showing that Nav1.5 and Nav1.8 coassociate when
expressed together. The observed functional inter-
action between Nav1.5 and Nav1.8 may suggest either
a direct physical interaction between the 2 channels
or an indirect interaction within a larger protein
complex. SCN10A-WT causes a gain of function of
Nav1.5 current, whereas SCN10A mutants (R14L and
R1268Q) cause a loss of function of Nav1.5 current,
which is expected to reduce excitability and lead to
development of the arrhythmogenic substrate
responsible for BrS and ERS as well as CCD, VT/VF,
AF, RBBB, and bradycardia.
STUDY LIMITATIONS. Of the 16 missense mutations
uncovered in this study, only 2 were functionally
characterized. Despite these limitations, 13 of these
variants were totally absent from our own ethnically
matched controls and are either absent or negligibly
present in all available public databases. Moreover,
these mutations are located in highly conserved res-
idues and are predicted to be pathogenic by in silico
prediction tools.
Our Co-IP analysis pointing to a coassociation of
Nav1.5 and Nav1.8 proteins was performed after
coexpression of SCN5A and SCN10A in HEK cells.
Ideally, these studies should be performed in native
human ventricular myocytes. This, however, must
await the availability of more reliable Nav1.8-speciﬁc
antibodies. Additional studies are needed to expand
the size of the cohort and to conduct functional
expression of WT and mutant SCN10A in native
myocytes or alternatively in induced pluripotent
stem cell–derived cardiomyocytes.
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CENTRAL ILLUSTRATION Proposed Mechanism by Which SCN10A Mutation Causes Brugada Syndrome
(A) SCN5A and SCN10A, genes encoding cardiac and neuronal sodium channels, are found in close proximity on chromosome 3. Our study
suggests that mutations in SCN10A can lead to a loss of function in sodium channel current (INa) and thus contribute to the manifestation of
Brugada syndrome, a sudden cardiac death syndrome. (B) The data suggest physical association of the 2 channel proteins (NaV1.5 and NaV1.8)
in the plasma membrane. (C) Our study identiﬁes SCN10A as a major susceptibility gene for BrS, thus greatly enhancing our ability to genotype
and risk stratify probands and family members. ECG ¼ electrocardiogram.
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77CONCLUSIONS
The ﬁndings of this study extend our knowledge of
the role of Nav1.8 in the heart and provide an expla-
nation for why SCN10A variants cause conduction and
rhythm disturbances, some of which were previouslyidentiﬁed by genome-wide association studies. Our
data identify SCN10A as a new BrS susceptibility gene
and a potential target for genetic screening and
antiarrhythmic intervention. We showed colocaliza-
tion and coassociation of Nav1.8 and Nav1.5 in
the plasma membrane and a gain of function of
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: BrS
and ERS are responsible for ventricular ﬁbrillation and
sudden cardiac death of young adults. Fewer than
35% of BrS probands have genetically identiﬁed
pathogenic variants. The identiﬁcation of SCN10A as a
major susceptibility gene for BrS and ERS greatly en-
hances the ability to risk stratify probands and family
members by genotyping.
TRANSLATIONAL OUTLOOK 1: The ability of
mutant neuronal sodium channels to cause a loss of
cardiac sodium channel activity provides insights into
mechanisms by which SCN10A variants may contribute
to overlap syndromes such as BrS, ERS, cardiac con-
duction disease, and various bradycardia phenotypes.
TRANSLATIONAL OUTLOOK 2: These ﬁndings
help to delineate the role of neuronal sodium chan-
nels in the electrical function of the heart.
Hu et al. J A C C V O L . 6 4 , N O . 1 , 2 0 1 4
SCN10A Mutations Associated With BrS J U L Y 8 , 2 0 1 4 : 6 6 – 7 9
78SCN10A-WT and loss of function of SCN10A mutants
on Nav1.5 INa. Male patients with BrS who are 11 to
50 years of age and present with a prolonged PRI
and QRS interval, VT/VF, ERS, and/or symptoms
(syncope, SCD, chest pain) have the highest proba-
bility of carrying an SCN10A variant. The spectrum
of SCN10A arrhythmic phenotypes, including BrS,
ERS, CCD, VT/VF, AF, RBBB, and bradycardia, is
similar to that of SCN5A variants. With a yield of
16.7% for SCN10A, a genotype can now be identiﬁed
in more than 50% of BrS probands.
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